PT2694101T - Composições farmacêutivas para prevenção e/ou tratamento de doença por vih em seres humanos - Google Patents

Composições farmacêutivas para prevenção e/ou tratamento de doença por vih em seres humanos

Info

Publication number
PT2694101T
PT2694101T PT127219210T PT12721921T PT2694101T PT 2694101 T PT2694101 T PT 2694101T PT 127219210 T PT127219210 T PT 127219210T PT 12721921 T PT12721921 T PT 12721921T PT 2694101 T PT2694101 T PT 2694101T
Authority
PT
Portugal
Prior art keywords
humans
treating
preventing
pharmaceutical compositions
hiv disease
Prior art date
Application number
PT127219210T
Other languages
English (en)
Portuguese (pt)
Inventor
Andrieu Jean-Marie
Lu Louis
Original Assignee
Université Paris Descartes
Biovaxim Ltd
Inst De Rech Pour Le Développement (Ird)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46969619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2694101(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université Paris Descartes, Biovaxim Ltd, Inst De Rech Pour Le Développement (Ird) filed Critical Université Paris Descartes
Publication of PT2694101T publication Critical patent/PT2694101T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT127219210T 2011-04-06 2012-04-06 Composições farmacêutivas para prevenção e/ou tratamento de doença por vih em seres humanos PT2694101T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2011/072481 2011-04-06
US201161534088P 2011-09-13 2011-09-13
CNPCT/CN2012/070761 2012-01-30
US201261609051P 2012-03-09 2012-03-09

Publications (1)

Publication Number Publication Date
PT2694101T true PT2694101T (pt) 2016-12-19

Family

ID=46969619

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127219210T PT2694101T (pt) 2011-04-06 2012-04-06 Composições farmacêutivas para prevenção e/ou tratamento de doença por vih em seres humanos

Country Status (20)

Country Link
US (1) US9839684B2 (enExample)
EP (3) EP2694101B1 (enExample)
JP (1) JP6054370B2 (enExample)
KR (1) KR101814857B1 (enExample)
CN (1) CN105709221B (enExample)
AP (1) AP2013007166A0 (enExample)
AU (1) AU2012238351B2 (enExample)
BR (1) BR112013025481B8 (enExample)
CA (1) CA2832022C (enExample)
CL (1) CL2013002836A1 (enExample)
DK (1) DK2694101T3 (enExample)
ES (1) ES2606511T3 (enExample)
IL (1) IL228666A (enExample)
MX (1) MX343037B (enExample)
PH (1) PH12013502064A1 (enExample)
PL (1) PL2694101T3 (enExample)
PT (1) PT2694101T (enExample)
RU (1) RU2609769C2 (enExample)
SG (1) SG194079A1 (enExample)
WO (1) WO2012137071A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2554106T3 (es) * 2001-06-21 2015-12-16 Genentech, Inc. Formulación de liberación sostenida
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
US10857223B2 (en) * 2014-06-10 2020-12-08 Case Western Reserve University Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection
CA2975247C (en) * 2015-01-30 2023-05-23 The University Of Tokyo Lactic-acid-bacteria-containing composition, oral pharmaceutical composition for treating hpv infection and/or hpv-associated tumors, and mucosal immunity-inducing agent
US11077185B2 (en) 2019-03-21 2021-08-03 21C Bio Vaccine to pathogenic immune activation cells during infections
EP3941517A1 (en) * 2019-03-21 2022-01-26 21C Bio Vaccine to pathogenic immune activation cells during infections
KR102507852B1 (ko) 2020-01-10 2023-03-09 이뮤노바이옴 주식회사 신규한 락토바실러스 플란타룸(Lactobacillus plantarum) 균주, 균주 유래 다당체 및 이의 용도
EP4288091A4 (en) * 2021-02-02 2025-07-02 Provaxus Inc NOVEL IMMUNOMODULATION PLATFORM AND METHODS OF USE

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL82104A0 (en) 1986-04-08 1987-10-30 Usa Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins
JPS6485072A (en) 1987-09-25 1989-03-30 Nat Inst Health Recombinant vaccinia virus
JPH01148183A (ja) 1987-12-04 1989-06-09 Hiroshi Shibuta 組み換えワクチニアウイルス
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5861282A (en) 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
CA2068713A1 (en) 1989-11-20 1991-05-21 Omar K. Haffar Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
DE69131513T3 (de) 1990-03-21 2005-05-25 Geneart Gmbh Für abgeänderte retrovirale GAG-Polypeptide kodierende DNA-Sequenzen und diese enthaltende Impfstoffe oder Aggregate davon
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
ATE241696T1 (de) 1991-06-14 2003-06-15 Virogenetics Corp Rekombinanter hiv-spezifischer impfstoff aus poxviru
DK0538496T3 (da) 1991-08-26 2004-02-23 Baxter Healthcare Sa Rekombinant fjerkrækoppevirus med intakt FPV tk-gen
DE4141741A1 (de) 1991-12-13 1993-06-17 Gisela Kielmann Verfahren zur bekaempfung des human imune deficiency virus
US6511845B1 (en) 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
US6136318A (en) 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
JPH07170982A (ja) 1993-09-09 1995-07-11 Nisshin Oil Mills Ltd:The ワクチンおよびその製造方法
WO1995007099A1 (en) 1993-09-09 1995-03-16 The Nisshin Oil Mills, Ltd. Vaccine and process for producing the same
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
WO1996011708A1 (en) 1994-10-18 1996-04-25 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
CA2223591A1 (en) 1995-06-07 1996-12-19 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US5741492A (en) 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
JPH1085072A (ja) 1996-09-13 1998-04-07 Kichinosuke Takemaru 家具転倒防止器具
US6001155A (en) 1997-03-17 1999-12-14 Pease; John R. Polyphasic pressurized homogenizer
HRP980143A2 (en) * 1997-04-09 1999-02-28 Soo Sung Ko 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
US5895758A (en) * 1997-06-10 1999-04-20 Bio-Energy Systems Strain of lactobacillus Plantarum
EP0991767A1 (en) 1997-06-11 2000-04-12 Institut Pasteur Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
JP3899165B2 (ja) 1997-08-06 2007-03-28 ビー・エル・オートテック株式会社 ロボットアームの過負荷保護装置
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6121021A (en) 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
US7189402B1 (en) 1998-02-06 2007-03-13 Research Development Foundation Live vaccine for human immunodeficiency virus
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
US20040009936A1 (en) 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン
EP1084709A1 (en) 1999-09-17 2001-03-21 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Oral recombinant lactobacilli vaccines
JP2003512077A (ja) 1999-10-26 2003-04-02 インターナショナル エイズ バクシーン イニシアティブ アルファウイルスレプリコンを発現する侵襲性細菌
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US20040101957A1 (en) 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
CA2422882A1 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
WO2002031168A2 (en) 2000-10-10 2002-04-18 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
GB0030857D0 (en) 2000-12-18 2001-01-31 Medical Res Council Therapeutic compositions
KR20020059856A (ko) 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
DE60234018D1 (de) 2001-03-08 2009-11-26 Univ Emory Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene
WO2002102409A1 (en) 2001-06-19 2002-12-27 Medical Research Council Inactivated mycobacterial ompatb and uses thereof
US20040253210A1 (en) 2001-08-30 2004-12-16 Marjorie Robert-Guroff Adenovirus type7 vectors
US20070077257A1 (en) 2001-09-14 2007-04-05 Emini Emilio A Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications
AU2002364952B2 (en) 2001-11-14 2008-04-10 Novavax, Inc. Mycobacterial vaccine
US20030133912A1 (en) 2001-12-11 2003-07-17 Davidson Beverly L. Receptor-targeted adenoviral vectors
US20040009937A1 (en) 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
CN1646020A (zh) 2002-01-31 2005-07-27 圣必健公司 将核酸和/或蛋白质导入呼吸系统的方法与制剂
EP1499736B1 (en) 2002-04-26 2009-03-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Improved chimeric glycoproteins and pseudotyped lentiviral vectors
JP2003321391A (ja) 2002-04-30 2003-11-11 Japan Science & Technology Corp 組換えワクシニアウイルスを用いたｈｉｖワクチン
DE10221411B4 (de) 2002-05-14 2004-07-08 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Rekombinantes Fowlpox-Virus
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EP1534306A2 (en) * 2002-05-31 2005-06-01 Ciphergen Biosystems, Inc. Defensins: use as antiviral agents
CN1490056A (zh) 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� 针对hiv-1的免疫方法和组合物
EP2359851A3 (en) 2003-03-28 2011-08-31 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
JP2007518460A (ja) 2003-05-09 2007-07-12 イントラヴァック インコーポレーテッド 皮内、皮下及び筋肉内注射用の無針注射器及びアンプル
US20100189747A1 (en) 2003-07-31 2010-07-29 Raymond Weinstein Compositions and methods for treating or preventing hiv infection
AP2006003530A0 (en) * 2003-08-28 2006-02-28 Immune Response Corp Inc Immunogenic HIV compositions and related methods.
JP2007037402A (ja) 2003-11-28 2007-02-15 Primmune:Kk 抗ヒト免疫不全ウイルス感染防御用キメラ５型／３５型アデノウイルスベクター
WO2005111205A1 (en) 2004-05-18 2005-11-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US8541167B2 (en) * 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
WO2006012320A1 (en) 2004-06-25 2006-02-02 Dow Agrosciences Llc Process for the preparation of 4-trifluoromethyl-2(1h)-pyridinone
WO2006026667A2 (en) 2004-08-27 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
BRPI0516314A (pt) * 2004-10-04 2008-09-02 Biovaxim Ltd uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv
JP5122983B2 (ja) 2005-02-24 2013-01-16 メディカル リサーチ カウンシル Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用
CN103088060A (zh) 2005-05-12 2013-05-08 葛兰素集团有限公司 疫苗组合物
EP1723965A1 (en) 2005-05-18 2006-11-22 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
EP2046352A4 (en) 2006-06-06 2012-03-21 Univ Mcgill Fermented milk product and use thereof
EP2144626B8 (en) 2007-04-12 2015-02-18 Mico Bio, Inc. Tuberculosis vaccine and method of using same
WO2009093900A1 (en) 2008-01-25 2009-07-30 Stichting Top Institute Food And Nutrition Mid-log phase lactic acid bacteria for inducing immune tolerance in a subject

Also Published As

Publication number Publication date
PL2694101T3 (pl) 2017-07-31
US20140302089A1 (en) 2014-10-09
AP2013007166A0 (en) 2013-10-31
BR112013025481B1 (pt) 2020-06-23
JP2014511856A (ja) 2014-05-19
PH12013502064A1 (en) 2019-07-03
DK2694101T3 (en) 2017-01-09
IL228666A (en) 2017-12-31
SG194079A1 (en) 2013-11-29
EP3000476A1 (en) 2016-03-30
RU2609769C2 (ru) 2017-02-02
AU2012238351A1 (en) 2013-10-24
US9839684B2 (en) 2017-12-12
MX343037B (es) 2016-10-20
WO2012137071A3 (en) 2012-11-29
NZ616283A (en) 2014-10-31
CA2832022C (en) 2019-01-08
ES2606511T3 (es) 2017-03-24
AU2012238351B2 (en) 2016-11-24
EP2694101B1 (en) 2016-09-14
EP3173096A1 (en) 2017-05-31
CN105709221B (zh) 2020-11-17
BR112013025481B8 (pt) 2022-11-08
BR112013025481A2 (pt) 2018-12-11
JP6054370B2 (ja) 2016-12-27
MX2013011540A (es) 2014-04-16
EP2694101A2 (en) 2014-02-12
KR101814857B1 (ko) 2018-01-04
RU2013147745A (ru) 2015-05-20
WO2012137071A2 (en) 2012-10-11
CL2013002836A1 (es) 2014-07-25
KR20140042800A (ko) 2014-04-07
CN105709221A (zh) 2016-06-29
IL228666A0 (en) 2013-12-31
CA2832022A1 (en) 2012-11-10

Similar Documents

Publication Publication Date Title
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
PT2740793T (pt) Composição de fármacos para o tratamento e/ou a prevenção de cancro
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
PL2740795T3 (pl) Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
PL2740798T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworom
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
PT2729151T (pt) Composição farmacêutica, métodos de tratamento e suas utilizações
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
IL224545A (en) Combined Pharmaceuticals for the Treatment and Prevention of Infectious Diseases
IL235923B (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
IL252566B (en) Pharmacy preparations and methods
IL228666A (en) Pharmaceuticals for the prevention and / or treatment of HIV in humans
IL230957B (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
GB201303868D0 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
IL228705A (en) Derivatives of Reliable Phenoxy-Ethyl, Pharmaceutical Preparations Containing and Using Them
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
IL221087A (en) Pharmacy or nutritional composition
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
GB201208315D0 (en) Pharmaceutical methods and compositions
ZA201307390B (en) Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
PT3539540T (pt) Inibidor de sglt2 1-cloro-4-(beta-d-glucopiranos-1-il)-2-[4-((s)-tetra-hidrofurano-3-iloxi)-benzil]-benzeno em combinação com insulina para utilização num método para redução do risco de hipoglicemia